Prion protein self-interactions: A gateway to novel therapeutic strategies?

Vaccine

Volumn 28, Issue 49, 2010, Pages 7810-7823

  Rigter, Alan ^a   Langeveld, Jan P M ^a   van Zijderveld, Fred G ^a   Bossers, Alex ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Prion protein; Protein interaction; Scrapie; Self interaction; Therapy; TSE

Indexed keywords

ACRIDINE MUSTARD; CALPASTATIN; CAVEOLIN; CHLORPROMAZINE; CONGO RED; CURCUMIN; DOXYCYCLINE; FC RECEPTOR; LAMININ RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEPACRINE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NERVE CELL ADHESION MOLECULE; PENTOSAN POLYSULFATE; POLYAMIDOAMIDE; POLYETHYLENEIMINE; POLYMER; POLYPROPYLENEIMINE; PORPHYRIN DERIVATIVE; PRION PROTEIN; PRION PROTEIN ANTIBODY; PRION PROTEIN MONOCLONAL ANTIBODY; PROTEIN KINASE ZAP 70; PROTEOHEPARAN SULFATE; QUININE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD BRAIN BARRIER; BOVINE SPONGIFORM ENCEPHALOPATHY; CARBOXY TERMINAL SEQUENCE; CENTRAL NERVOUS SYSTEM; CREUTZFELDT JAKOB DISEASE; DRUG PROTEIN BINDING; HUMAN; IMMUNOTHERAPY; LIVER DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; SCRAPIE; VARIANT CREUTZFELDT JAKOB DISEASE;

ANIMALS; HUMANS; PRION DISEASES; PRIONS; PROTEIN FOLDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PRPC PROTEINS; PRPSC PROTEINS;

EID: 78349306852     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.012     Document Type: Article

References (172)

1. Griffith J.S. Self-replication and scrapie. Nature 1967, 215(105):1043-1044.
2. Prusiner S.B. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216(4542):136-144.
3. Will R.G., Ironside J.W., Zeidler M., Cousens S.N., Estibeiro K., Alperovitch A., et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996, 347(9006):921-925.
4. Harris D.A. Trafficking, turnover and membrane topology of PrP. Br Med Bull 2003, 66:71-85.
5. Harris D.A. Cellular biology of prion diseases. Clin Microbiol Rev 1999, 12(3):429-444.
6. Kaneko K., Vey M., Scott M., Pilkuhn S., Cohen F.E., Prusiner S.B. COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform. Proc Natl Acad Sci USA 1997, 94(6):2333-2338.
7. Hegde R.S., Tremblay P., Groth D., DeArmond S.J., Prusiner S.B., Lingappa V.R. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 1999, 402(6763):822-826.
8. Gu Y., Luo X., Basu S., Fujioka H., Singh N. Cell-specific metabolism and pathogenesis of transmembrane prion protein. Mol Cell Biol 2006, 26(7):2697-2715.
9. Riesner D. Biochemistry and structure of PrP(C) and PrP(Sc). Br Med Bull 2003, 66:21-33.
10. van Keulen L.J., Schreuder B.E., Vromans M.E., Langeveld J.P., Smits M.A. Pathogenesis of natural scrapie in sheep. Arch Virol Suppl 2000, 16:57-71.
11. Cashman N.R., Caughey B. Prion diseases-close to effective therapy?. Nat Rev Drug Discov 2004, 3(10):874-884.
12. van Keulen L.J., Bossers A., van Zijderveld F. TSE pathogenesis in cattle and sheep. Vet Res 2008, 39(4):24.
13. van Keulen L.J., Vromans M.E., Dolstra C.H., Bossers A., van Zijderveld F.G. Pathogenesis of bovine spongiform encephalopathy in sheep. Arch Virol 2008, 153(3):445-453.
14. Horiuchi M., Yamazaki N., Ikeda T., Ishiguro N., Shinagawa M. A cellular form of prion protein (PrPC) exists in many non-neuronal tissues of sheep. J Gen Virol 1995, 76(Pt 10):2583-2587.
15. Silva J.L., Lima L.M., Foguel D., Cordeiro Y. Intriguing nucleic-acid-binding features of mammalian prion protein. Trends Biochem Sci 2008, 33(3):132-140.
16. Rieger R., Edenhofer F., Lasmezas C.I., Weiss S. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med 1997, 3(12):1383-1388.
17. Gauczynski S., Peyrin J.M., Haik S., Leucht C., Hundt C., Rieger R., et al. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J 2001, 20(21):5863-5875.
18. Gauczynski S., Nikles D., El-Gogo S., Papy-Garcia D., Rey C., Alban S., et al. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J Infect Dis 2006, 194(5):702-709.
19. Hundt C., Peyrin J.M., Haik S., Gauczynski S., Leucht C., Rieger R., et al. Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. EMBO J 2001, 20(21):5876-5886.
20. Shyng S.L., Moulder K.L., Lesko A., Harris D.A. The N-terminal domain of a glycolipid-anchored prion protein is essential for its endocytosis via clathrin-coated pits. J Biol Chem 1995, 270(24):14793-14800.
21. Sunyach C., Jen A., Deng J., Fitzgerald K.T., Frobert Y., Grassi J., et al. The mechanism of internalization of glycosylphosphatidylinositol-anchored prion protein. EMBO J 2003, 22(14):3591-3601.
22. Taylor D.R., Watt N.T., Perera W.S., Hooper N.M. Assigning functions to distinct regions of the N-terminus of the prion protein that are involved in its copper-stimulated, clathrin-dependent endocytosis. J Cell Sci 2005, 118(Pt 21):5141-5153.
23. Taylor D.R., Hooper N.M. The low-density lipoprotein receptor-related protein 1 (LRP1) mediates the endocytosis of the cellular prion protein. Biochem J 2007, 402(1):17-23.
24. Parkyn C.J., Vermeulen E.G., Mootoosamy R.C., Sunyach C., Jacobsen C., Oxvig C., et al. LRP1 controls biosynthetic and endocytic trafficking of neuronal prion protein. J Cell Sci 2008, 121(Pt 6):773-783.
25. Roucou X., LeBlanc A.C. Cellular prion protein neuroprotective function: implications in prion diseases. J Mol Med 2005, 83(1):3-11.
26. Li A., Harris D.A. Mammalian prion protein suppresses Bax-induced cell death in yeast. J Biol Chem 2005, 280(17):17430-17434.
27. Zanata S.M., Lopes M.H., Mercadante A.F., Hajj G.N., Chiarini L.B., Nomizo R., et al. Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection. EMBO J 2002, 21(13):3307-3316.
28. Lopes M.H., Hajj G.N., Muras A.G., Mancini G.L., Castro R.M., Ribeiro K.C., et al. Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling pathways. J Neurosci 2005, 25(49):11330-11339.
29. Caetano F.A., Lopes M.H., Hajj G.N., Machado C.F., Pinto Arantes C., Magalhaes A.C., et al. Endocytosis of prion protein is required for ERK1/2 signaling induced by stress-inducible protein 1. J Neurosci 2008, 28(26):6691-6702.
30. Coitinho A.S., Lopes M.H., Hajj G.N., Rossato J.I., Freitas A.R., Castro C.C., et al. Short-term memory formation and long-term memory consolidation are enhanced by cellular prion association to stress-inducible protein 1. Neurobiol Dis 2007, 26(1):282-290.
31. Weise J., Sandau R., Schwarting S., Crome O., Wrede A., Schulz-Schaeffer W., et al. Deletion of cellular prion protein results in reduced Akt activation, enhanced postischemic caspase-3 activation, and exacerbation of ischemic brain injury. Stroke 2006, 37(5):1296-1300.
32. Coitinho A.S., Roesler R., Martins V.R., Brentani R.R., Izquierdo I. Cellular prion protein ablation impairs behavior as a function of age. Neuroreport 2003, 14(10):1375-1379.
33. Criado J.R., Sanchez-Alavez M., Conti B., Giacchino J.L., Wills D.N., Henriksen S.J., et al. Mice devoid of prion protein have cognitive deficits that are rescued by reconstitution of PrP in neurons. Neurobiol Dis 2005, 19(1-2):255-265.
34. Mouillet-Richard S., Schneider B., Pradines E., Pietri M., Ermonval M., Grassi J., et al. Cellular prion protein signaling in serotonergic neuronal cells. Ann N Y Acad Sci 2007, 1096:106-119.
35. Mattei V., Garofalo T., Misasi R., Circella A., Manganelli V., Lucania G., et al. Prion protein is a component of the multimolecular signaling complex involved in T cell activation. FEBS Lett 2004, 560(1-3):14-18.
36. Santuccione A., Sytnyk V., Leshchyns'ka I., Schachner M. Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth. J Cell Biol 2005, 169(2):341-354.
37. Graner E., Mercadante A.F., Zanata S.M., Martins V.R., Jay D.G., Brentani R.R. Laminin-induced PC-12 cell differentiation is inhibited following laser inactivation of cellular prion protein. FEBS Lett 2000, 482(3):257-260.
38. Satoh J., Obayashi S., Misawa T., Sumiyoshi K., Oosumi K., Tabunoki H. Protein microarray analysis identifies human cellular prion protein interactors. Neuropathol Appl Neurobiol 2009, 35(1):16-35.
39. Haigh C.L., Lewis V.A., Vella L.J., Masters C.L., Hill A.F., Lawson V.A., et al. PrPC-related signal transduction is influenced by copper, membrane integrity and the alpha cleavage site. Cell Res 2009, 19(9):1062-1078.
40. Stohr J., Weinmann N., Wille H., Kaimann T., Nagel-Steger L., Birkmann E., et al. Mechanisms of prion protein assembly into amyloid. Proc Natl Acad Sci USA 2008, 105(7):2409-2414.
41. Caughey B., Kocisko D.A., Raymond G.J., T L.P. Aggregates of scrapie-associated prion protein induce the cell-free conversion of protease-sensitive prion protein to the protease-resistant state. Chem Biol 1995, 2(12):807-817.
42. Wille H., Michelitsch M.D., Guenebaut V., Supattapone S., Serban A., Cohen F.E., et al. Structural studies of the scrapie prion protein by electron crystallography. Proc Natl Acad Sci USA 2002, 99(6):3563-3568.
43. Govaerts C., Wille H., Prusiner S.B., Cohen F.E. Evidence for assembly of prions with left-handed beta-helices into trimers. Proc Natl Acad Sci USA 2004, 101(22):8342-8347.
44. Langedijk J.P., Fuentes G., Boshuizen R., Bonvin A.M. Two-rung model of a left-handed beta-helix for prions explains species barrier and strain variation in transmissible spongiform encephalopathies. J Mol Biol 2006, 360(4):907-920.
45. Jenkins D.C., Sylvester I.D., Pinheiro T.J. The elusive intermediate on the folding pathway of the prion protein. FEBS J 2008, 275(6):1323-1335.
46. Hosszu L.L., Trevitt C.R., Jones S., Batchelor M., Scott D.J., Jackson G.S., et al. Conformational properties of beta-PrP. J Biol Chem 2009, 284(33):21981-21990.
47. Gerber R., Tahiri-Alaoui A., Hore P.J., James W. Oligomerization of the human prion protein proceeds via a molten globule intermediate. J Biol Chem 2007, 282(9):6300-6307.
48. Apetri A.C., Maki K., Roder H., Surewicz W.K. Early intermediate in human prion protein folding as evidenced by ultrarapid mixing experiments. J Am Chem Soc 2006, 128(35):11673-11678.
49. Silveira J.R., Hughson A.G., Caughey B. Fractionation of prion protein aggregates by asymmetrical flow field-flow fractionation. Methods Enzymol 2006, 412:21-33.
50. Kocisko D.A., Come J.H., Priola S.A., Chesebro B., Raymond G.J., Lansbury P.T., et al. Cell-free formation of protease-resistant prion protein. Nature 1994, 370(6489):471-474.
51. Caughey B. Interactions between prion protein isoforms: the kiss of death?. Trends Biochem Sci 2001, 26(4):235-242.
52. Raymond G.J., Bossers A., Raymond L.D., O'Rourke K.I., McHolland L.E., Bryant P.K., et al. Evidence of a molecular barrier limiting susceptibility of humans, cattle and sheep to chronic wasting disease. EMBO J 2000, 19(17):4425-4430.
53. Supattapone S. Prion protein conversion in vitro. J Mol Med 2004, 82(6):348-356.
54. Castilla J., Morales R., Saá P., Barria M., Gambetti P., Soto C. Cell-free propagation of prion strains. EMBO J 2008, 27(19):2557-2566.
55. Weber P., Giese A., Piening N., Mitteregger G., Thomzig A., Beekes M., et al. Generation of genuine prion infectivity by serial PMCA. Vet Microbiol 2007, 123(4):346-357.
56. Deleault N.R., Harris B.T., Rees J.R., Supattapone S. Formation of native prions from minimal components in vitro. Proc Natl Acad Sci USA 2007, 104(23):9741-9746.
57. Baskakov I.V., Legname G., Baldwin M.A., Prusiner S.B., Cohen F.E. Pathway complexity of prion protein assembly into amyloid. J Biol Chem 2002, 277(24):21140-21148.
58. Lu B.Y., Chang J.Y. Isolation of isoforms of mouse prion protein with PrP(SC)-like structural properties. Biochemistry 2001, 40(44):13390-13396.
59. Bossers A., de Vries R., Smits M.A. Susceptibility of sheep for scrapie as assessed by in vitro conversion of nine naturally occurring variants of PrP. J Virol 2000, 74(3):1407-1414.
60. Dubois M.A., Sabatier P., Durand B., Calavas D., Ducrot C., Chalvet-Monfray K. Multiplicative genetic effects in scrapie disease susceptibility. C R Biol 2002, 325(5):565-570.
61. Sabuncu E., Petit S., Le Dur A., Lan Lai T., Vilotte J.L., Laude H., et al. PrP polymorphisms tightly control sheep prion replication in cultured cells. J Virol 2003, 77(4):2696-2700.
62. Tranulis M.A. Influence of the prion protein gene Prnp, on scrapie susceptibility in sheep. Apmis 2002, 110(1):33-43.
63. Rigter A., Bossers A. Sheep scrapie susceptibility-linked polymorphisms do not modulate the initial binding of cellular to disease-associated prion protein prior to conversion. J Gen Virol 2005, 86(Pt 9):2627-2634.
64. Rigter A., Langeveld J.P., Timmers-Parohi D., Jacobs J.G., Moonen P.L., Bossers A. Mapping of possible prion protein self-interaction domains using peptide arrays. BMC Biochem 2007, 8:6.
65. Rigter A., Priem J., Timmers-Parohi D., Langeveld J.P., van Zijderveld F.G., Bossers A. Prion protein self-peptides modulate prion interactions and conversion. BMC Biochem 2009, 10:29.
66. Jacobs J.G., Langeveld J.P., Biacabe A.G., Acutis P.L., Polak M.P., Gavier-Widen D., et al. Molecular discrimination of atypical bovine spongiform encephalopathy strains from a geographical region spanning a wide area in Europe. J Clin Microbiol 2007, 45(6):1821-1829.
67. Thuring C.M., Erkens J.H., Jacobs J.G., Bossers A., Van Keulen L.J., Garssen G.J., et al. Discrimination between scrapie and bovine spongiform encephalopathy in sheep by molecular size, immunoreactivity, and glycoprofile of prion protein. J Clin Microbiol 2004, 42(3):972-980.
68. Moroncini G., Kanu N., Solforosi L., Abalos G., Telling G.C., Head M., et al. Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. Proc Natl Acad Sci USA 2004, 101(28):10404-10409.
69. Riek R., Hornemann S., Wider G., Glockshuber R., Wüthrich K. NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231). FEBS Lett 1997, 413(2):282-288.
70. Solforosi L., Bellon A., Schaller M., Cruite J.T., Abalos G.C., Williamson R.A. Toward molecular dissection of PrPC-PrPSc interactions. J Biol Chem 2007, 282(10):7465-7471.
71. Surewicz W.K., Jones E.M., Apetri A.C. The emerging principles of Mammalian prion propagation and transmissibility barriers: insight from studies in vitro. Acc Chem Res 2006, 39(9):654-662.
72. Beringue V., Vilette D., Mallinson G., Archer F., Kaisar M., Tayebi M., et al. PrPSc binding antibodies are potent inhibitors of prion replication in cell lines. J Biol Chem 2004, 279(38):39671-39676.
73. Enari M., Flechsig E., Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci USA 2001, 98(16):9295-9299.
74. Korth C., Stierli B., Streit P., Moser M., Schaller O., Fischer R., et al. Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature 1997, 390(6655):74-77.
75. Peretz D., Williamson R.A., Kaneko K., Vergara J., Leclerc E., Schmitt-Ulms G., et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001, 412(6848):739-743.
76. Perrier V., Solassol J., Crozet C., Frobert Y., Mourton-Gilles C., Grassi J., et al. Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. J Neurochem 2004, 89(2):454-463.
77. Heppner F.L., Musahl C., Arrighi I., Klein M.A., Rulicke T., Oesch B., et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 2001, 294(5540):178-182.
78. Bueler H., Aguzzi A., Sailer A., Greiner R.A., Autenried P., Aguet M., et al. Mice devoid of PrP are resistant to scrapie. Cell 1993, 73(7):1339-1347.
79. Mallucci G., Dickinson A., Linehan J., Klohn P.C., Brandner S., Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003, 302(5646):871-874.
80. Bossers A., Belt P., Raymond G.J., Caughey B., de Vries R., Smits M.A. Scrapie susceptibility-linked polymorphisms modulate the in vitro conversion of sheep prion protein to protease-resistant forms. Proc Natl Acad Sci USA 1997, 94(10):4931-4936.
81. Daude N., Marella M., Chabry J. Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J Cell Sci 2003, 116(Pt 13):2775-2779.
82. Pfeifer A., Eigenbrod S., Al-Khadra S., Hofmann A., Mitteregger G., Moser M., et al. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest 2006, 116(12):3204-3210.
83. White M.D., Farmer M., Mirabile I., Brandner S., Collinge J., Mallucci G.R. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci USA 2008, 105(29):10238-10243.
84. Singer O., Yanai A., Verma I.M. Silence of the genes. Proc Natl Acad Sci USA 2004, 101(15):5313-5314.
85. Wiznerowicz M., Trono D. Harnessing HIV for therapy, basic research and biotechnology. Trends Biotechnol 2005, 23(1):42-47.
86. Horiuchi M., Priola S.A., Chabry J., Caughey B. Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci USA 2000, 97(11):5836-5841.
87. Palmer M.S., Dryden A.J., Hughes J.T., Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 1991, 352(6333):340-342.
88. Bossers A. Prion disease: susceptibility and transmissibility; in vivo and in vitro studies with sheep scrapie 1999.
89. Holscher C., Delius H., Burkle A. Overexpression of nonconvertible PrPc delta114-121 in scrapie-infected mouse neuroblastoma cells leads to trans-dominant inhibition of wild-type PrP(Sc) accumulation. J Virol 1998, 72(2):1153-1159.
90. Caplazi P.A., O'Rourke K.I., Baszler T.V. Resistance to scrapie in PrP ARR/ARQ heterozygous sheep is not caused by preferential allelic use. J Clin Pathol 2004, 57(6):647-650.
91. Groschup M.H., Lacroux C., Buschmann A., Luhken G., Mathey J., Eiden M., et al. Classic scrapie in sheep with the ARR/ARR prion genotype in Germany and France. Emerg Infect Dis 2007, 13(8):1201-1207.
92. Le Dur A., Beringue V., Andreoletti O., Reine F., Lai T.L., Baron T., et al. A newly identified type of scrapie agent can naturally infect sheep with resistant PrP genotypes. Proc Natl Acad Sci USA 2005, 102(44):16031-16036.
93. Buschmann A., Luhken G., Schultz J., Erhardt G., Groschup M.H. Neuronal accumulation of abnormal prion protein in sheep carrying a scrapie-resistant genotype (PrPARR/ARR). J Gen Virol 2004, 85(Pt 9):2727-2733.
94. Baylis M., McIntyre K.M. Transmissible spongiform encephalopathies: scrapie control under new strain. Nature 2004, 432(7019):810-811.
95. Toupet K., Compan V., Crozet C., Mourton-Gilles C., Mestre-Frances N., Ibos F., et al. Effective gene therapy in a mouse model of prion diseases. PLoS ONE 2008, 3(7):e2773.
96. Chabry J., Priola S.A., Wehrly K., Nishio J., Hope J., Chesebro B. Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J Virol 1999, 73(8):6245-6250.
97. Mohan J., Bruce M.E., Mabbott N.A. Follicular dendritic cell dedifferentiation reduces scrapie susceptibility following inoculation via the skin. Immunology 2005, 114(2):225-234.
98. Glaysher B.R., Mabbott N.A. Role of the GALT in scrapie agent neuroinvasion from the intestine. J Immunol 2007, 178(6):3757-3766.
99. van Keulen L.J., Vromans M.E., van Zijderveld F.G. Early and late pathogenesis of natural scrapie infection in sheep. Apmis 2002, 110(1):23-32.
100. Heppner F.L., Christ A.D., Klein M.A., Prinz M., Fried M., Kraehenbuhl J.P., et al. Transepithelial prion transport by M cells. Nat Med 2001, 7(9):976-977.
101. Mishra R.S., Basu S., Gu Y., Luo X., Zou W.Q., Mishra R., et al. Protease-resistant human prion protein and ferritin are cotransported across Caco-2 epithelial cells: implications for species barrier in prion uptake from the intestine. J Neurosci 2004, 24(50):11280-11290.
102. Raymond C.R., Aucouturier P., Mabbott N.A. In vivo depletion of CD11c+ cells impairs scrapie agent neuroinvasion from the intestine. J Immunol 2007, 179(11):7758-7766.
103. Mabbott N.A., Young J., McConnell I., Bruce M.E. Follicular dendritic cell dedifferentiation by treatment with an inhibitor of the lymphotoxin pathway dramatically reduces scrapie susceptibility. J Virol 2003, 77(12):6845-6854.
104. Montrasio F., Frigg R., Glatzel M., Klein M.A., Mackay F., Aguzzi A., et al. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science 2000, 288(5469):1257-1259.
105. Supattapone S., Wille H., Uyechi L., Safar J., Tremblay P., Szoka F.C., et al. Branched polyamines cure prion-infected neuroblastoma cells. J Virol 2001, 75(7):3453-3461.
106. Solassol J., Crozet C., Perrier V., Leclaire J., Beranger F., Caminade A.M., et al. Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J Gen Virol 2004, 85(Pt 6):1791-1799.
107. Oishi T., Hagiwara K., Kinumi T., Yamakawa Y., Nishijima M., Nakamura K., et al. Effects of beta-sheet breaker peptide polymers on scrapie-infected mouse neuroblastoma cells and their affinities to prion protein fragment PrP(81-145). Org Biomol Chem 2003, 1(15):2626-2629.
108. Reilly C.E. Beta-sheet breaker peptides reverse conformation of pathogenic prion proteins. J Neurol 2000, 247(4):319-320.
109. Soto C., Kascsak R.J., Saborio G.P., Aucouturier P., Wisniewski T., Prelli F., et al. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 2000, 355(9199):192-197.
110. Harris D.A., Huber M.T., van Dijken P., Shyng S.L., Chait B.T., Wang R. Processing of a cellular prion protein: identification of N- and C-terminal cleavage sites. Biochemistry 1993, 32(4):1009-1016.
111. Pan K.M., Stahl N., Prusiner S.B. Purification and properties of the cellular prion protein from Syrian hamster brain. Protein Sci 1992, 1(10):1343-1352.
112. Taraboulos A., Scott M., Semenov A., Avrahami D., Laszlo L., Prusiner S.B. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol 1995, 129(1):121-132.
113. Yadavalli R., Guttmann R.P., Seward T., Centers A.P., Williamson R.A., Telling G.C. Calpain-dependent endoproteolytic cleavage of PrPSc modulates scrapie prion propagation. J Biol Chem 2004, 279(21):21948-21956.
114. Wang X., Wang F., Sy M.S., Ma J. Calpain and other cytosolic proteases can contribute to the degradation of retro-translocated prion protein in the cytosol. J Biol Chem 2005, 280(1):317-325.
115. Kristensson K., Feuerstein B., Taraboulos A., Hyun W.C., Prusiner S.B., DeArmond S.J. Scrapie prions alter receptor-mediated calcium responses in cultured cells. Neurology 1993, 43(11):2335-2341.
116. O'Donovan C.N., Tobin D., Cotter T.G. Prion protein fragment PrP-(106-126) induces apoptosis via mitochondrial disruption in human neuronal SH-SY5Y cells. J Biol Chem 2001, 276(47):43516-43523.
117. Gabizon R., McKinley M.P., Groth D., Prusiner S.B. Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc Natl Acad Sci USA 1988, 85(18):6617-6621.
118. Horiuchi M., Caughey B. Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J 1999, 18(12):3193-3203.
119. Sigurdsson E.M., Brown D.R., Daniels M., Kascsak R.J., Kascsak R., Carp R., et al. Immunization delays the onset of prion disease in mice. Am J Pathol 2002, 161(1):13-17.
120. Sigurdsson E.M., Sy M.S., Li R., Scholtzova H., Kascsak R.J., Kascsak R., et al. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci Lett 2003, 336(3):185-187.
121. Schwarz A., Kratke O., Burwinkel M., Riemer C., Schultz J., Henklein P., et al. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett 2003, 350(3):187-189.
122. Nikles D., Bach P., Boller K., Merten C.A., Montrasio F., Heppner F.L., et al. Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. J Virol 2005, 79(7):4033-4042.
123. Handisurya A., Gilch S., Winter D., Shafti-Keramat S., Maurer D., Schatzl H.M., et al. Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells. FEBS J 2007, 274(7):1747-1758.
124. White A.R., Enever P., Tayebi M., Mushens R., Linehan J., Brandner S., et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003, 422(6927):80-83.
125. Cardinale A., Biocca S. The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases. Trends Mol Med 2008, 14(9):373-380.
126. Solforosi L., Criado J.R., McGavern D.B., Wirz S., Sanchez-Alavez M., Sugama S., et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 2004, 303(5663):1514-1516.
127. Farquhar C.F., Dickinson A.G. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J Gen Virol 1986, 67(Pt 3):463-473.
128. Caughey B., Raymond G.J. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol 1993, 67(2):643-650.
129. Adjou K.T., Simoneau S., Sales N., Lamoury F., Dormont D., Papy-Garcia D., et al. A novel generation of heparan sulfate mimetics for the treatment of prion diseases. J Gen Virol 2003, 84(Pt 9):2595-2603.
130. Larramendy-Gozalo C., Barret A., Daudigeos E., Mathieu E., Antonangeli L., Riffet C., et al. Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases. J Gen Virol 2007, 88(Pt 3):1062-1067.
131. Todd N.V., Morrow J., Doh-ura K., Dealler S., O'Hare S., Farling P., et al. Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J Infect 2005, 50(5):394-396.
132. Whittle I.R., Knight R.S., Will R.G. Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease. Acta Neurochir (Wien) 2006, 148(6):677. 9; discussion 679.
133. Bone I., Belton L., Walker A.S., Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol 2008, 15(5):458-464.
134. Pocchiari M., Ladogana A., Graziano S., Puopolo M. Creutzfeldt-Jakob disease: hopes for therapy. Eur J Neurol 2008, 15(5):435-436.
135. Poli G., Martino P.A., Villa S., Carcassola G., Giannino M.L., Dall'Ara P., et al. Evaluation of anti-prion activity of congo red and its derivatives in experimentally infected hamsters. Arzneimittelforschung 2004, 54(7):406-415.
136. Caughey B., Race R.E. Potent inhibition of scrapie-associated PrP accumulation by congo red. J Neurochem 1992, 59(2):768-771.
137. Sellarajah S., Lekishvili T., Bowring C., Thompsett A.R., Rudyk H., Birkett C.R., et al. Synthesis of analogues of Congo red and evaluation of their anti-prion activity. J Med Chem 2004, 47(22):5515-5534.
138. Caughey B., Raymond L.D., Raymond G.J., Maxson L., Silveira J., Baron G.S. Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J Virol 2003, 77(9):5499-5502.
139. Riemer C., Burwinkel M., Schwarz A., Gultner S., Mok S.W., Heise I., et al. Evaluation of drugs for treatment of prion infections of the central nervous system. J Gen Virol 2008, 89(Pt 2):594-597.
140. Caughey W.S., Raymond L.D., Horiuchi M., Caughey B. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci USA 1998, 95(21):12117-12122.
141. Priola S.A., Raines A., Caughey W.S. Porphyrin and phthalocyanine antiscrapie compounds. Science 2000, 287(5457):1503-1506.
142. Priola S.A., Raines A., Caughey W. Prophylactic and therapeutic effects of phthalocyanine tetrasulfonate in scrapie-infected mice. J Infect Dis 2003, 188(5):699-705.
143. Barret A., Tagliavini F., Forloni G., Bate C., Salmona M., Colombo L., et al. Evaluation of quinacrine treatment for prion diseases. J Virol 2003, 77(15):8462-8469.
144. Doh-Ura K., Iwaki T., Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000, 74(10):4894-4897.
145. Doh-ura K., Ishikawa K., Murakami-Kubo I., Sasaki K., Mohri S., Race R., et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 2004, 78(10):4999-5006.
146. Korth C., May B.C., Cohen F.E., Prusiner S.B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001, 98(17):9836-9841.
147. Murakami-Kubo I., Doh-Ura K., Ishikawa K., Kawatake S., Sasaki K., Kira J., et al. Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J Virol 2004, 78(3):1281-1288.
148. Kobayashi Y., Hirata K., Tanaka H., Yamada T. Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft-an EEG evaluation. Rinsho Shinkeigaku 2003, 43(7):403-408.
149. Nakajima M., Yamada T., Kusuhara T., Furukawa H., Takahashi M., Yamauchi A., et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 2004, 17(3):158-163.
150. Martinez-Lage J.F., Rabano A., Bermejo J., Martinez Perez M., Guerrero M.C., Contreras M.A., et al. Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine. Surg Neurol 2005, 64(6):542. 5, discussion 545.
151. Wroe S.J., Pal S., Siddique D., Hyare H., Macfarlane R., Joiner S., et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006, 368(9552):2061-2067.
152. Satoh K., Shirabe S., Eguchi K., Yamauchi A., Kataoka Y., Niwa M., et al. Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease. Cell Mol Neurobiol 2004, 24(6):873-875.
153. Scoazec J.Y., Krolak-Salmon P., Casez O., Besson G., Thobois S., Kopp N., et al. Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2003, 53(4):546-547.
154. Forloni G., Salmona M., Marcon G., Tagliavini F. Tetracyclines and prion infectivity. Infect Disord Drug Targets 2009, 9(1):23-30.
155. Morel E., Andrieu T., Casagrande F., Gauczynski S., Weiss S., Grassi J., et al. Bovine prion is endocytosed by human enterocytes via the 37kDa/67kDa laminin receptor. Am J Pathol 2005, 167(4):1033-1042.
156. Horonchik L., Tzaban S., Ben-Zaken O., Yedidia Y., Rouvinski A., Papy-Garcia D., et al. Heparan sulfate is a cellular receptor for purified infectious prions. J Biol Chem 2005, 280(17):17062-17067.
157. Shyng S.L., Heuser J.E., Harris D.A. A glycolipid-anchored prion protein is endocytosed via clathrin-coated pits. J Cell Biol 1994, 125(6):1239-1250.
158. Mouillet-Richard S., Ermonval M., Chebassier C., Laplanche J.L., Lehmann S., Launay J.M., et al. Signal transduction through prion protein. Science 2000, 289(5486):1925-1928.
159. Mouillet-Richard S., Pietri M., Schneider B., Vidal C., Mutel V., Launay J.M., et al. Modulation of serotonergic receptor signaling and cross-talk by prion protein. J Biol Chem 2005, 280(6):4592-4601.
160. Mattei V., Garofalo T., Misasi R., Gizzi C., Mascellino M.T., Dolo V., et al. Association of cellular prion protein with gangliosides in plasma membrane microdomains of neural and lymphocytic cells. Neurochem Res 2002, 27(7-8):743-749.
161. Coitinho A.S., Freitas A.R., Lopes M.H., Hajj G.N., Roesler R., Walz R., et al. The interaction between prion protein and laminin modulates memory consolidation. Eur J Neurosci 2006, 24(11):3255-3264.
162. Sakudo A., Lee D.C., Li S., Nakamura T., Matsumoto Y., Saeki K., et al. PrP cooperates with STI1 to regulate SOD activity in PrP-deficient neuronal cell line. Biochem Biophys Res Commun 2005, 328(1):14-19.
163. Tilly G., Chapuis J., Vilette D., Laude H., Vilotte J.L. Efficient and specific down-regulation of prion protein expression by RNAi. Biochem Biophys Res Commun 2003, 305(3):548-551.
164. Priola S.A., Caughey B., Race R.E., Chesebro B. Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol 1994, 68(8):4873-4878.
165. Chabry J., Caughey B., Chesebro B. Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem 1998, 273(21):13203-13207.
166. Mabbott N.A., Mackay F., Minns F., Bruce M.E. Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie. Nat Med 2000, 6(7):719-720.
167. Ehlers B., Diringer H. Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 1984, 65(Pt 8):1325-1330.
168. Kimberlin R.H., Walker C.A. Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob Agents Chemother 1986, 30(3):409-413.
169. Gilch S., Winklhofer K.F., Groschup M.H., Nunziante M., Lucassen R., Spielhaupter C., et al. Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease. EMBO J 2001, 20(15):3957-3966.
170. Nunziante M., Kehler C., Maas E., Kassack M.U., Groschup M., Schatzl H.M. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication. J Cell Sci 2005, 118(Pt 21):4959-4973.
171. Caughey W.S., Priola S.A., Kocisko D.A., Raymond L.D., Ward A., Caughey B. Cyclic tetrapyrrole sulfonation, metals, and oligomerization in antiprion activity. Antimicrob Agents Chemother 2007, 51(11):3887-3894.
172. Collins S.J., Lewis V., Brazier M., Hill A.F., Fletcher A., Masters C.L. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002, 52(4):503-506.